Skip to main content

Advertisement

SpringerLink
Log in

Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lindquist M (2008) VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42:409–419

    Google Scholar 

  2. Mimura H, Kobayashi K, Xu L, Hashimoto M, Ejiri Y, Hosoda M, et al. (2015) Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4. Drug Metab Pharmacokinet 30:105–110

    Article  CAS  PubMed  Google Scholar 

  3. Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. (2012) Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 74:490–500

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hartmann G, Kim H, Piquette-Miller M (2001) Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol 2:189–199

    Article  Google Scholar 

Download references

Acknowledgments

Vigibase data were provided by the Uppsala Monitoring Centre, but the study results and conclusions are those of the authors and not necessarily those of the Uppsala Monitoring Centre, national pharmacovigilance centers, or WHO.

Author information

Authors and Affiliations

  1. Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France

    B. Clarivet, P. Robin, J. Lebrun, D. Hillaire-Buys, V. Brés & J. L. Faillie

  2. Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Montpellier University Hospital, Montpellier, France

    Y. M. Pers, R. Ferreira & C. Jorgensen

Authors
  1. B. Clarivet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. M. Pers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Lebrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Jorgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Hillaire-Buys
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. Brés
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. L. Faillie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Clarivet.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clarivet, B., Robin, P., Pers, Y.M. et al. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein. Eur J Clin Pharmacol 72, 1413–1414 (2016). https://doi.org/10.1007/s00228-016-2107-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-016-2107-0

Keywords

Search

Navigation